Products

Our current treatments.

Generic tiopronin delayed-release tablets

Approved in the US.


Read the full Prescribing Information
Learn more

ORMALVI (dichlorphenamide) Tablets

Approved in the US.


Read the full Prescribing Information
Learn more

TASCENSO ODT® (fingolimod)

Approved in the US.


Read the full Prescribing Information
Learn more

SAJAZIR™ (icatibant) Injection

Approved in the US.


Read the full Prescribing Information
Learn more

JAVYGTOR™ (sapropterin dihydrochloride)

Approved in the US.


Read the full Prescribing Information
Learn more

NITYR® (nitisinone) Tablets

Approved in the US, Australia, New Zealand, the Kingdom of Saudi Arabia, the Kingdom of Morocco and Israel in 2, 5 and 10 mg strengths and in the UK, and Egypt in 10 mg strength. Cycle Pharmaceuticals’ nitisinone products are also approved under a different name, NITISINONE TABLETS, in Canada in 2, 5, and 10 mg strengths. Registration conditions differ internationally.


Read the full Prescribing Information
Learn more

For NITYR® distribution information in the US market please contact +1-800-847-8714.

For NITYR® distribution information in Canada and all other markets please contact: sales-distribution@cyclepharma.com


Patient Support Programme

Life-changing treatments need life-improving product support to match. That’s why we created Cycle Vita™, our patient support programme for patients in the US. It delivers individualised emotional, financial,* and product support that patients need at every step of their journey.

Find out more

Reporting an Adverse Event

To report an Adverse Event please click below

Report an Adverse Event

State Regulations Information

Information for US Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131

Download PDF

*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360- 8482.